Biotechnology

TransCode Therapeutics

TransCode Therapeutics released FY2025 Q3 earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -5.8248

TransCode Therapeutics released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -81.1122

TransCode Therapeutics released FY2025 Q2 earnings on August 14 (EST) with actual revenue of USD 0 and EPS of USD -5.1298

TransCode Therapeutics released FY2025 Semi-Annual Earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -32.4478

TransCode Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -70.1575 (forecast USD --)

TransCode Therapeutics' Cancer Treatment Drug TTX-MC138 Phase 1a Initial Dosing Successfully Completed

TransCode Therapeutics Inc. Seeks Hearing to Address Delisting Risk

TransCode Therapeutics Announces Reverse Split

TransCode Therapeutics Announces Positive Progress in TTX-MC138 Phase 1a Clinical Trial

TransCode Therapeutics released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 300K), actual EPS USD -271.5735

TransCode Therapeutics released FY2024 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 300K), actual EPS USD -1.317K

TransCode Therapeutics Announces Sale of 10.25 Million Shares of Common Stock and Warrants

TransCode Therapeutics, Inc. Shareholders Approve Proposals for Series C and D Warrants

TransCode Therapeutics released FY2024 9 Months Earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD -146.0634

TransCode Therapeutics released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 300K), actual EPS USD -146.0634

TransCode Therapeutics Launches Phase 1 Clinical Trial

TransCode Therapeutics released FY2024 Semi-Annual earnings on August 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

TransCode Therapeutics released FY2024 Q2 earnings on August 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0.

Transcode Therapeutics Inc Announces Proposed Public Offering of Common Stock

TransCode Therapeutics, Inc. announces significant progress

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

Foxx Development

Palatin Tech

Mobile-Health Network Solutions

Nuvve

Datavault AI

CCSC Tech

Iveda Solutions

Harrison Global

Alps

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap